RPRX News and Press, Royalty Pharma plc From 06/03/24

2024-06-03 17:21:16 ET More on Royalty Pharma Royalty Pharma: Solid Start Of The Year, Buy Confirmed Agios in pact with Royalty Pharma for brain tumor candidate Cytokinetics to get up to $575M in funding from Royalty Pharma Seeking Alpha’s Quant Rating...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $500 million of 5.150% Notes due 2029 (the “...

2024-06-03 10:15:02 ET UBS analyst issues NEUTRAL recommendation for RPRX on June 3, 2024 08:53AM ET. The previous analyst recommendation was Buy. RPRX was trading at $27.35 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst ...

2024-06-03 10:00:06 ET Ashwani Verma from UBS issued a price target of $28.00 for RPRX on 2024-06-03 08:53:00. The adjusted price target was set to $28.00. At the time of the announcement, RPRX was trading at $27.35. The overall price target consensus is at $49.00 with h...

2024-06-02 17:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-29 20:54:18 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value decreased from $27.3B to $26.9B in Q1 2024. The number of holdings in the portfolio increased from 79 to 83. The largest five individual stock positions are Visa, Workday, Amazon.com, Philip Morri...

2024-05-28 07:45:02 ET More on Agios, Royalty Pharma, etc. Royalty Pharma: Solid Start Of The Year, Buy Confirmed Royalty Pharma PLC (RPRX) Q1 2024 Earnings Call Transcript Agios Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation Cytokinetic...

Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20,...

2024-05-27 10:05:29 ET Summary Arrowhead Pharmaceuticals' stock has dropped more than 70% from its June 2021 high, causing concerns about its near-term outlook. The company's lead therapy, plozasiran, is currently behind Ionis Pharmaceuticals' olezarsen for two hypertriglyceridemi...

2024-05-22 17:08:12 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics CEO Blum says positioned to marke...